RhumbLine Advisers
FATE icon

RhumbLine Advisers’s Fate Therapeutics FATE Stock Holding History

RhumbLine Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Sell
132,308
-14,453
-10% -$17.6K ﹤0.01% 3226
2025
Q4 		$144K Sell
146,761
-7,325
-5% -$8.8K ﹤0.01% 3324
2025
Q3 		$194K Sell
154,086
-1,772
-1% -$1.91K ﹤0.01% 3234
2025
Q2 		$175K Buy
155,858
+5,610
+4% +$6.52K ﹤0.01% 3304
2025
Q1 		$119K Sell
150,248
-8,924
-6% -$10.9K ﹤0.01% 3330
2024
Q4 		$263K Buy
159,172
+2,174
+1% +$5.48K ﹤0.01% 3067
2024
Q3 		$549K Sell
156,998
-3,003
-2% -$11.7K ﹤0.01% 2640
2024
Q2 		$525K Buy
160,001
+15,825
+11% +$69.3K ﹤0.01% 2649
2024
Q1 		$1.06M Buy
144,176
+3,841
+3% +$23.8K ﹤0.01% 2222
2023
Q4 		$525K Sell
140,335
-7
-0% -$17 ﹤0.01% 2628
2023
Q3 		$298K Buy
140,342
+1,634
+1% +$5.41K ﹤0.01% 2940
2023
Q2 		$660K Buy
138,708
+22,159
+19% +$122K ﹤0.01% 2515
2023
Q1 		$664K Buy
116,549
+2,608
+2% +$15.7K ﹤0.01% 2306
2022
Q4 		$1.15M Buy
113,941
+3,588
+3% +$67.4K ﹤0.01% 2054
2022
Q3 		$2.47M Buy
110,353
+8,975
+9% +$259K ﹤0.01% 1641
2022
Q2 		$2.51M Buy
101,378
+11,996
+13% +$331K ﹤0.01% 1648
2022
Q1 		$3.46M Buy
89,382
+758
+0.9% +$29.4K ﹤0.01% 1541
2021
Q4 		$5.18M Sell
88,624
-3,049
-3% -$173K 0.01% 1334
2021
Q3 		$5.43M Buy
91,673
+2,109
+2% +$165K 0.01% 1315
2021
Q2 		$7.77M Buy
89,564
+37
+0% +$2.98K 0.01% 1159
2021
Q1 		$7.38M Sell
89,527
-5,738
-6% -$550K 0.01% 1182
2020
Q4 		$8.66M Buy
95,265
+5,871
+7% +$365K 0.01% 1019
2020
Q3 		$3.57M Sell
89,394
-13,494
-13% -$471K 0.01% 1360
2020
Q2 		$3.53M Buy
102,888
+14,908
+17% +$444K 0.01% 1403
2020
Q1 		$1.95M Buy
87,980
+3,290
+4% +$83.2K ﹤0.01% 1559
2019
Q4 		$1.66M Buy
84,690
+6,875
+9% +$109K ﹤0.01% 1868
2019
Q3 		$1.21M Buy
77,815
+721
+0.9% +$13.8K ﹤0.01% 1949
2019
Q2 		$1.56M Sell
77,094
-3,126
-4% -$56.3K ﹤0.01% 1871
2019
Q1 		$1.41M Buy
80,220
+841
+1% +$13.3K ﹤0.01% 1885
2018
Q4 		$1.02M Buy
79,379
+35,315
+80% +$492K ﹤0.01% 2001
2018
Q3 		$718K Sell
44,064
-3,050
-6% -$36.1K ﹤0.01% 2138
2018
Q2 		$534K Buy
47,114
+2,728
+6% +$30.1K ﹤0.01% 2278
2018
Q1 		$433K Buy
44,386
+10,946
+33% +$105K ﹤0.01% 2270
2017
Q4 		$204K Sell
33,440
-8,087
-19% -$36.1K ﹤0.01% 2622
2017
Q3 		$164K Buy
41,527
+560
+1% +$1.9K ﹤0.01% 2801
2017
Q2 		$133K Buy
+40,967
New +$157K ﹤0.01% 2860

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's FATE Position: Q1 2026 in Review

RhumbLine Advisers reduced its Fate Therapeutics (FATE) stake by 9.8% in Q1 2026, selling an estimated $17.6K and leaving 132,308 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #3226.

RhumbLine Advisers first reported a position in FATE in Q2 2017 and has held it in 36 quarters since. The position peaked at $8.66M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • RhumbLine Advisers held 132,308 shares of Fate Therapeutics worth $159K as of Q1 2026.
  • RhumbLine Advisers sold 14,453 Fate Therapeutics shares in Q1 2026, an estimated $17.6K.
  • Fate Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3226 holding.
  • RhumbLine Advisers first reported a position in Fate Therapeutics in Q2 2017 and has held it in 36 quarters since.
  • RhumbLine Advisers's Fate Therapeutics position peaked at $8.66M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.